--- title: "Dipeptide Diaminobutyroyl Benzylamide Diacetate" canonical_url: https://bestpeptidecalculator.app/library/syn-ake description: "Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug." updated: 2026-11-07 publisher: Peptide Library notice: "Research and educational use only. Not medical advice." --- # Dipeptide Diaminobutyroyl Benzylamide Diacetate Dipeptide Diaminobutyroyl Benzylamide Diacetate (also called Waglerin-1 mimetic or Tripeptide-3) is a cosmetic nicotinic antagonist mimetic. This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction. Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug. Also known as: Waglerin-1 mimetic, Tripeptide-3. Categories: Cosmetic, Experimental. ## Classification - Type: Cosmetic nicotinic antagonist mimetic - Mechanism class: nAChR-mimetic cosmetic peptide - Development stage: Research only - Regulatory class: Research compound, not FDA-approved ## Mechanism This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction. Applied topically the intent is to reduce the microcontractions of facial expression muscles that produce dynamic lines, giving a mechanism conceptually parallel to botulinum toxin but acting on the receptor rather than on vesicle fusion, and far weaker. Whether a topically applied dipeptide reaches the neuromuscular junction in meaningful concentration is the central unresolved question; evidence is largely supplier-derived. Targets: Muscle nAChR (model systems). Origin: Synthetic tripeptide analog of temple-viper waglerin-1. ## Properties - Molecular formula: C23H37N5O7 (salt forms vary) - CAS number: 823202-99-9 - Half-life: Topical; systemic PK not established ## Evidence - Evidence level: Insufficient Evidence - Highest documented: Early or uncontrolled human studies - Human trials: 1 - Controlled human trials: 0 - Preclinical sources: 1 - Latest source: 2026 No human dose is established for this compound. Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess. ### Studies 1. Zhu M et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. Int J Cosmet Sci. 2026. 2026. Human study (early or uncontrolled). Population: Two clinical studies: 50 participants (static wrinkles) and 42 participants (dynamic wrinkles). Clinical scores for static wrinkles improved 35%–69% and dynamic wrinkles 10%–13% (all p < 0.001); a control group is not stated in the abstract [Source](https://pubmed.ncbi.nlm.nih.gov/41668671/) 2. Gok B et al. Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. J Biomol Struct Dyn. 2024. 2024. Preclinical: in vitro (cells or tissue). Population: Computer docking models and cell and bacterial tests. Predicted binding to MMPs and SIRT1, concentration-dependent antioxidant activity, and safety in cytotoxicity and Ames tests. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/37349941/) ## Safety Side effects: Irritation; Redness. Risks: Cosmetic only. Human safety basis: No controlled human safety data Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use.. ## Regulatory status Dipeptide Diaminobutyroyl Benzylamide Diacetate is not an FDA-approved product. It is sold for laboratory research and has no approved medical use. - FDA status: Not Approved - WADA status: Permitted - Availability: OTC / Supplement ## Frequently asked questions ### What is Dipeptide Diaminobutyroyl Benzylamide Diacetate? Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug. ### How does Dipeptide Diaminobutyroyl Benzylamide Diacetate work? This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction. ### Is Dipeptide Diaminobutyroyl Benzylamide Diacetate FDA approved? No. Dipeptide Diaminobutyroyl Benzylamide Diacetate is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. ### What is the half-life of Dipeptide Diaminobutyroyl Benzylamide Diacetate? Reported half-life for Dipeptide Diaminobutyroyl Benzylamide Diacetate is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied. ### Is Dipeptide Diaminobutyroyl Benzylamide Diacetate banned in sport? Dipeptide Diaminobutyroyl Benzylamide Diacetate is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use. ### What peptides are similar to Dipeptide Diaminobutyroyl Benzylamide Diacetate? Compounds most often compared with Dipeptide Diaminobutyroyl Benzylamide Diacetate include Acetyl Hexapeptide-8, Acetyl Octapeptide-3, Acetyl Tetrapeptide-3 and AHK-Cu. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ. ## References - [PubChem SYN-AKE](https://pubchem.ncbi.nlm.nih.gov/compound/Dipeptide%20diaminobutyroyl%20benzylamide%20diacetate) - [Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests — J Biomol Struct Dyn, 2024](https://pubmed.ncbi.nlm.nih.gov/37349941/) - [Microemulsions and Nanoemulsions for Topical Delivery of Tripeptide-3: From Design of Experiment to Anti-Sebum Efficacy on Facial Skin — Pharmaceutics, 2024](https://pubmed.ncbi.nlm.nih.gov/38675215/) - [Role of Peptides in Skeletal Muscle Wasting: A Scoping Review — J Cachexia Sarcopenia Muscle, 2025](https://pubmed.ncbi.nlm.nih.gov/41231146/) - [Antidiabetic Potential of a Trimeric Anthranilic Acid Peptide Isolated from Malbranchea flocciformis — Chem Biodivers, 2024](https://pubmed.ncbi.nlm.nih.gov/38102075/)